Journal Article

Angiotensin 1–7 in an experimental septic shock model

Taccone, Fabio Silvio, Garcia, Bruno, Su, Fuhong, Moiroux-Sahroui, Alexander, Favory, Raphaël, Moreau, Anthony, Dewachter, Laurence, Creteur, Jacques, Khaldi, Amina, Vincent, Jean-Louis, Annoni, Filippo, Herpain, Antoine, Manicone, Francesca

2023

Overview

Background Alterations in the renin–angiotensin system have been implicated in the pathophysiology of septic shock. In particular, angiotensin 1–7 (Ang-(1–7)), an anti-inflammatory heptapeptide, has been hypothesized to have beneficial effects. The aim of the present study was to test the effects of Ang-(1–7) infusion on the development and severity of septic shock. Methods This randomized, open-label, controlled study was performed in 14 anesthetized and mechanically ventilated sheep. Immediately after sepsis induction by bacterial peritonitis, animals received either Ang-(1–7) ( n  = 7) or placebo ( n  = 7) intravenously. Fluid resuscitation, antimicrobial therapy, and peritoneal lavage were initiated 4 h after sepsis induction. Norepinephrine administration was titrated to maintain mean arterial pressure (MAP) between 65 and 75 mmHg. Results There were no differences in baseline characteristics between groups. Septic shock was prevented in 6 of the 7 animals in the Ang-(1–7) group at the end of the 24-h period. Fluid balance and MAP were similar in the two groups; however, MAP was achieved with a mean norepinephrine dose of 0.4 μg/kg/min in the Ang-(1–7) group compared to 4.3 μg/kg/min in the control group. Heart rate and cardiac output index were lower in the Ang (1–7) than in the control group, as were plasma interleukin-6 levels, and creatinine levels. Platelet count and PaO 2 /FiO 2 ratio were higher in the Ang-(1–7) group. Mean arterial lactate at the end of the experiment was 1.6 mmol/L in the Ang-(1–7) group compared to 7.4 mmol/L in the control group. Conclusions In this experimental septic shock model, early Ang-(1–7) infusion prevented the development of septic shock, reduced norepinephrine requirements, limited interleukine-6 increase and prevented renal dysfunction.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Abdomen / Analysis / Angiotensin / Angiotensin (1–7) / Angiotensin I - pharmacology / Angiotensin I - therapeutic use / Animals / Care and treatment / Catheters / Circulatory failure / Critical care / Critical Care Medicine / Cytokines / Diagnosis / Dosage and administration / Emergency Medicine / Experiments / Feces / Inflammation / Intensive / Interleukins / Life Sciences / Medicine / Medicine & Public Health / Noradrenaline / Norepinephrine - pharmacology / Norepinephrine - therapeutic use / Pathophysiology / Physiology, Pathological / Pulmonary arteries / Renin-angiotensin system / Sepsis / Sepsis - drug therapy / Septic shock / Sheep / Shock, Septic / Urine / Vasopressors / Veins & arteries / Ventilators